Inclusion Criteria:~* Meets National Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's
Disease~* Has completed participation in solanezumab Study LZAM or Study LZAN through 80 weeks~* Must continue
to have a reliable caregiver who is in frequent contact with the patient for the entire study~* Must have good
vein access to administer infusions~* Agrees not to participate in studies of any other investigational
compounds for the duration of their participation in Study LZAO~
